264 related articles for article (PubMed ID: 23750747)
21. Synthesis and evaluation of pegylated dendrimeric nanocarrier for pulmonary delivery of low molecular weight heparin.
Bai S; Ahsan F
Pharm Res; 2009 Mar; 26(3):539-48. PubMed ID: 19034631
[TBL] [Abstract][Full Text] [Related]
22. Dendrimer nanocarriers for transport modulation across models of the pulmonary epithelium.
Bharatwaj B; Mohammad AK; Dimovski R; Cassio FL; Bazito RC; Conti D; Fu Q; Reineke J; da Rocha SR
Mol Pharm; 2015 Mar; 12(3):826-38. PubMed ID: 25455560
[TBL] [Abstract][Full Text] [Related]
23. PEGylated PAMAM dendrimers as a potential drug delivery carrier: in vitro and in vivo comparative evaluation of covalently conjugated drug and noncovalent drug inclusion complex.
Jiang YY; Tang GT; Zhang LH; Kong SY; Zhu SJ; Pei YY
J Drug Target; 2010 Jun; 18(5):389-403. PubMed ID: 20055559
[TBL] [Abstract][Full Text] [Related]
24. Dendrimers as a carrier for pulmonary delivery of enoxaparin, a low-molecular weight heparin.
Bai S; Thomas C; Ahsan F
J Pharm Sci; 2007 Aug; 96(8):2090-106. PubMed ID: 17286291
[TBL] [Abstract][Full Text] [Related]
25. Cellular internalization and transport of biodegradable polyester dendrimers on a model of the pulmonary epithelium and their formulation in pressurized metered-dose inhalers.
Heyder RS; Zhong Q; Bazito RC; da Rocha SRP
Int J Pharm; 2017 Mar; 520(1-2):181-194. PubMed ID: 28161666
[TBL] [Abstract][Full Text] [Related]
26. Optimal PEGylation can improve the exposure of interferon in the lungs following pulmonary administration.
Mcleod VM; Chan LJ; Ryan GM; Porter CJ; Kaminskas LM
J Pharm Sci; 2015 Apr; 104(4):1421-30. PubMed ID: 25631360
[TBL] [Abstract][Full Text] [Related]
27. PEGylated lysine dendrimers for tumor-selective targeting after intravenous injection in tumor-bearing mice.
Okuda T; Kawakami S; Akimoto N; Niidome T; Yamashita F; Hashida M
J Control Release; 2006 Dec; 116(3):330-6. PubMed ID: 17118476
[TBL] [Abstract][Full Text] [Related]
28. Influence of dendrimer generation and polyethylene glycol length on the biodistribution of PEGylated dendrimers.
Kojima C; Regino C; Umeda Y; Kobayashi H; Kono K
Int J Pharm; 2010 Jan; 383(1-2):293-6. PubMed ID: 19761822
[TBL] [Abstract][Full Text] [Related]
29. Targeting hepatic cancer cells with pegylated dendrimers displaying N-acetylgalactosamine and SP94 peptide ligands.
Medina SH; Tiruchinapally G; Chevliakov MV; Durmaz YY; Stender RN; Ensminger WD; Shewach DS; Elsayed ME
Adv Healthc Mater; 2013 Oct; 2(10):1337-50. PubMed ID: 23554387
[TBL] [Abstract][Full Text] [Related]
30. X-ray computed tomography contrast agents prepared by seeded growth of gold nanoparticles in PEGylated dendrimer.
Kojima C; Umeda Y; Ogawa M; Harada A; Magata Y; Kono K
Nanotechnology; 2010 Jun; 21(24):245104. PubMed ID: 20498528
[TBL] [Abstract][Full Text] [Related]
31. PEGylated dendrimers with core functionality for biological applications.
Guillaudeu SJ; Fox ME; Haidar YM; Dy EE; Szoka FC; Fréchet JM
Bioconjug Chem; 2008 Feb; 19(2):461-9. PubMed ID: 18173227
[TBL] [Abstract][Full Text] [Related]
32. PEGylated dendrimer-entrapped gold nanoparticles for in vivo blood pool and tumor imaging by computed tomography.
Peng C; Zheng L; Chen Q; Shen M; Guo R; Wang H; Cao X; Zhang G; Shi X
Biomaterials; 2012 Feb; 33(4):1107-19. PubMed ID: 22061490
[TBL] [Abstract][Full Text] [Related]
33. Polyamidoamine dendrimers as novel potential absorption enhancers for improving the small intestinal absorption of poorly absorbable drugs in rats.
Lin Y; Fujimori T; Kawaguchi N; Tsujimoto Y; Nishimi M; Dong Z; Katsumi H; Sakane T; Yamamoto A
J Control Release; 2011 Jan; 149(1):21-8. PubMed ID: 20184931
[TBL] [Abstract][Full Text] [Related]
34. PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin.
Patel B; Gupta V; Ahsan F
J Control Release; 2012 Sep; 162(2):310-20. PubMed ID: 22800582
[TBL] [Abstract][Full Text] [Related]
35. The Pharmacokinetics and Biodistribution of a 64 kDa PolyPEG Star Polymer After Subcutaneous and Pulmonary Administration to Rats.
Khor SY; Hu J; McLeod VM; Quinn JF; Porter CJ; Whittaker MR; Kaminskas LM; Davis TP
J Pharm Sci; 2016 Jan; 105(1):293-300. PubMed ID: 26852861
[TBL] [Abstract][Full Text] [Related]
36. Polyethylene glycol-drug ester conjugates for prolonged retention of small inhaled drugs in the lung.
Bayard FJ; Thielemans W; Pritchard DI; Paine SW; Young SS; Bäckman P; Ewing P; Bosquillon C
J Control Release; 2013 Oct; 171(2):234-40. PubMed ID: 23916883
[TBL] [Abstract][Full Text] [Related]
37. The lungs as a portal of entry for systemic drug delivery.
Patton JS; Fishburn CS; Weers JG
Proc Am Thorac Soc; 2004; 1(4):338-44. PubMed ID: 16113455
[TBL] [Abstract][Full Text] [Related]
38. Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: a concise overview.
Mignani S; El Kazzouli S; Bousmina M; Majoral JP
Adv Drug Deliv Rev; 2013 Oct; 65(10):1316-30. PubMed ID: 23415951
[TBL] [Abstract][Full Text] [Related]
39. A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems.
Kaminskas LM; McLeod VM; Kelly BD; Sberna G; Boyd BJ; Williamson M; Owen DJ; Porter CJ
Nanomedicine; 2012 Jan; 8(1):103-11. PubMed ID: 21704192
[TBL] [Abstract][Full Text] [Related]
40. Local inflammation alters the lung disposition of a drug loaded pegylated liposome after pulmonary dosing to rats.
Haque S; Feeney O; Meeusen E; Boyd BJ; McIntosh MP; Pouton CW; Whittaker M; Kaminskas LM
J Control Release; 2019 Aug; 307():32-43. PubMed ID: 31152749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
